Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 1/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.49 |
| ▸ | MEN1 | O00255 | 4/20 | 0.49 |
| ▸ | MAPT | P10636 | 3/20 | 0.49 |
| ▸ | ATP4A | P20648 | 12/20 | 0.44 |
| ▸ | ATP4B | P51164 | 12/20 | 0.44 |
| ▸ | RAB9A | P51151 | 2/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4656600 | 1.00 | MAPK14 (0.52) | MAPK14KMT2AMEN1MAPTATP4A | |
| SCHEMBL4655643 | 1.00 | MAPK14 (0.52) | MAPK14KMT2AMEN1MAPTATP4A | |
| SCHEMBL5421143 | 0.90 | NPC1 (0.47) | KMT2AMEN1MAPTATP4AATP4B | |
| SCHEMBL5428907 | 0.90 | NPC1 (0.47) | KMT2AMEN1MAPTATP4AATP4B | |
| SCHEMBL4655753 | 0.90 | POLB (0.44) | MAPK14KMT2AMEN1MAPTATP4A | |
| SCHEMBL5424455 | 0.90 | KMT2A (0.48) | MAPK14KMT2AMEN1MAPTATP4A | |
| SCHEMBL5429241 | 0.88 | ATP4A (0.44) | KMT2AMEN1MAPTATP4AATP4B | |
| SCHEMBL4655600 | 0.87 | KMT2A (0.48) | MAPK14KMT2AMEN1MAPTATP4A | |
| SCHEMBL9100048 | 0.86 | KMT2A (0.48) | MAPK14KMT2AMEN1MAPTATP4A | |
| SCHEMBL4655485 | 0.86 | KMT2A (0.50) | MAPK14KMT2AMEN1MAPTATP4A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12030876-B2 | Aryl hydrocarbon receptor (AHR) agonists and uses thereof | Ikena Oncology, Inc. (US) | 2024-07-09 | — | — | US | disclosed |
| US-12030876-B2 | Aryl hydrocarbon receptor (AHR) agonists and uses thereof | Ikena Oncology, Inc. (US) | 2024-07-09 | — | — | US | disclosed |
| US-20230295147-A1 | ARYL HYDROCARBON RECEPTOR (AHR) AGONISTS AND USES THEREOF | ARYL THERAPEUTICS, INC. | 2023-09-21 | — | — | US | disclosed |
| US-20230295147-A1 | ARYL HYDROCARBON RECEPTOR (AHR) AGONISTS AND USES THEREOF | ARYL THERAPEUTICS, INC. | 2023-09-21 | — | — | US | disclosed |
| US-20210230153-A1 | ARYL HYDROCARBON RECEPTOR (AHR) AGONISTS AND USES THEREOF | ARYL THERAPEUTICS, INC. | 2021-07-29 | — | — | US | disclosed |
| EP-2460800-A1 | Substituted aminothiazole derivatives with anti-HCV activity | Achillion Pharmaceuticals, Inc. (US) | 2012-06-06 | — | — | EP | disclosed |
| US-20070213301-A1 | Substituted Aminothiazole Derivatives With Anti-HCV Activity | ACHILLION PHARMACEUTICALS, INC. (US) | 2007-09-13 | — | — | US | disclosed |
| US-20070213301-A1 | Substituted Aminothiazole Derivatives With Anti-HCV Activity | ACHILLION PHARMACEUTICALS, INC. (US) | 2007-09-13 | — | — | US | disclosed |
| US-20070213301-A1 | Substituted Aminothiazole Derivatives With Anti-HCV Activity | ACHILLION PHARMACEUTICALS, INC. (US) | 2007-09-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12030876-B2 | Aryl hydrocarbon receptor (AHR) agonists and uses thereof | AHR, ARNT, HCAR1 | MAPK14 4069/4885KMT2A 1031/4885MEN1 4851/4885 |
| US-20230295147-A1 | ARYL HYDROCARBON RECEPTOR (AHR) AGONISTS AND USES THEREOF | AHR, ARNT, HCAR1 | MAPK14 4069/4885KMT2A 1031/4885MEN1 4851/4885 |
| US-20070213301-A1 | Substituted Aminothiazole Derivatives With Anti-HCV Activity | EIF2AK2, BCAT1, IL4I1 | MAPK14 3629/4885KMT2A 2793/4885MEN1 4788/4885 |
| US-20210230153-A1 | ARYL HYDROCARBON RECEPTOR (AHR) AGONISTS AND USES THEREOF | AHR, ARNT, HCAR1 | MAPK14 4069/4885KMT2A 1031/4885MEN1 4851/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.